Becker, Richard C <br/><br/>
Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.  [electronic resource] 

 -  Thrombosis and haemostasis  Nov 2010 
 - 976-83 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>2567-689X 
<br/><br/><label>Standard No.: </label>10.1160/TH10-04-0247  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Coronary Syndrome--blood<br/>Administration, Oral<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Biomarkers--blood<br/>Blood Coagulation--drug effects<br/>Chi-Square Distribution<br/>Chromatography, Liquid<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Down-Regulation<br/>Enzyme-Linked Immunosorbent Assay<br/>Factor Xa--metabolism<br/>Factor Xa Inhibitors<br/>Female<br/>Fibrin Fibrinogen Degradation Products--metabolism<br/>Fibrinolytic Agents--administration & dosage<br/>Humans<br/>International Normalized Ratio<br/>Male<br/>Middle Aged<br/>Odds Ratio<br/>Partial Thromboplastin Time<br/>Peptide Fragments--blood<br/>Placebo Effect<br/>Prothrombin<br/>Pyrazoles--administration & dosage<br/>Pyridones--administration & dosage<br/>Tandem Mass Spectrometry<br/>Thrombin--metabolism<br/>Time Factors<br/>Treatment Outcome